Researchers working on custom CRISPR therapies said FDA expectations for individualized genetic medicines could make scaling difficult, citing stringent manufacturing and quality control requirements that could raise costs and complexity for smaller players. The concern follows recent momentum in the space and underscores the operational burden of bespoke manufacturing.